- Home
- HYPR vs PEPG Comparison
HYPR vs PEPG Comparison
Compare HYPR & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- PEPG
- Stock Information
- Founded
- HYPR 2014
- PEPG 2018
- Country
- HYPR United States
- PEPG United States
- Employees
- HYPR N/A
- PEPG N/A
- Industry
- HYPR Medical Specialities
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- HYPR Health Care
- PEPG Health Care
- Exchange
- HYPR Nasdaq
- PEPG Nasdaq
- Market Cap
- HYPR 54.6M
- PEPG 52.4M
- IPO Year
- HYPR N/A
- PEPG 2022
- Fundamental
- Price
- HYPR $0.80
- PEPG $1.50
- Analyst Decision
- HYPR Strong Buy
- PEPG Buy
- Analyst Count
- HYPR 3
- PEPG 3
- Target Price
- HYPR $1.06
- PEPG $7.67
- AVG Volume (30 Days)
- HYPR 6.2M
- PEPG 195.1K
- Earning Date
- HYPR 05-13-2025
- PEPG 05-08-2025
- Dividend Yield
- HYPR N/A
- PEPG N/A
- EPS Growth
- HYPR N/A
- PEPG N/A
- EPS
- HYPR N/A
- PEPG N/A
- Revenue
- HYPR $11,732,000.00
- PEPG N/A
- Revenue This Year
- HYPR $13.22
- PEPG N/A
- Revenue Next Year
- HYPR $24.57
- PEPG N/A
- P/E Ratio
- HYPR N/A
- PEPG N/A
- Revenue Growth
- HYPR 0.34
- PEPG N/A
- 52 Week Low
- HYPR $0.53
- PEPG $0.88
- 52 Week High
- HYPR $1.90
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- HYPR 56.58
- PEPG 50.24
- Support Level
- HYPR $0.61
- PEPG $1.35
- Resistance Level
- HYPR $1.19
- PEPG $1.55
- Average True Range (ATR)
- HYPR 0.12
- PEPG 0.15
- MACD
- HYPR 0.03
- PEPG -0.00
- Stochastic Oscillator
- HYPR 40.06
- PEPG 39.47
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.